Amir M Mohareb1, Naomi J Patel2, Xiaoqing Fu3, Arthur Y Kim4, Zachary S Wallace3, Emily P Hyle5. 1. A.M. Mohareb, MD, E.P. Hyle, MD, MSc, Medical Practice Evaluation Center, and Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School; amohareb@mgh.harvard.edu. 2. N.J. Patel, MD, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital. 3. X. Fu, MS, Z.S. Wallace, MD, MSc, Harvard Medical School, and Division of Rheumatology, Allergy and Immunology, and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital. 4. A.Y. Kim, MD, Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA. 5. A.M. Mohareb, MD, E.P. Hyle, MD, MSc, Medical Practice Evaluation Center, and Division of Infectious Diseases, Massachusetts General Hospital, and Harvard Medical School.
Abstract
OBJECTIVE: Hepatitis B virus (HBV) can reactivate among rheumatology patients initiating tocilizumab (TCZ) or tofacitinib (TOF). HBV screening is recommended by the Centers for Disease Control and Prevention (CDC), the American Association for the Study of Liver Diseases (AASLD), and the Canadian Rheumatology Association, but it is not explicitly recommended by the American College of Rheumatology. METHODS: We conducted a cross-sectional study to characterize HBV screening practices for adult rheumatology patients initiating TCZ or TOF before December 31, 2018, in the Greater Boston area. We classified appropriate HBV screening patterns prior to TCZ or TOF (i.e., HBV surface antigen [HBsAg], total core antibody [anti-HBcAb], and surface antibody [HBsAb]) as follows: complete (all 3 tested), partial (any 1 or 2 tests), or none. We determined the frequency of inappropriate HBV testing (HBV e-antigen, anti-HBcAb IgM, or HBV DNA without a positive HBsAg or total anti-HBcAb) and used multivariable regression to assess factors associated with complete HBV screening. RESULTS: Among 678 subjects initiating TCZ, 194 (29%) completed appropriate HBV screening, 307 (45%) had partial screening, and 177 (26%) had none. Among 391 subjects initiating TOF, 94 (24%) completed appropriate HBV screening, 195 (50%) had partial screening, and 102 (26%) had none. Inappropriate testing was performed in 22% of subjects. Race was associated with complete HBV screening (White vs non-White: OR 0.74, 95% CI 0.57-0.95), whereas prior immunosuppression was not (conventional synthetic disease-modifying antirheumatic drugs [DMARDs]: OR 1.05, 95% CI 0.72-1.55; biologic DMARDs: OR 0.73, 95% CI 0.48-1.12). CONCLUSION: Patients initiating TCZ or TOF are infrequently screened for HBV despite recommendations from the AASLD and CDC.
OBJECTIVE: Hepatitis B virus (HBV) can reactivate among rheumatology patients initiating tocilizumab (TCZ) or tofacitinib (TOF). HBV screening is recommended by the Centers for Disease Control and Prevention (CDC), the American Association for the Study of Liver Diseases (AASLD), and the Canadian Rheumatology Association, but it is not explicitly recommended by the American College of Rheumatology. METHODS: We conducted a cross-sectional study to characterize HBV screening practices for adult rheumatology patients initiating TCZ or TOF before December 31, 2018, in the Greater Boston area. We classified appropriate HBV screening patterns prior to TCZ or TOF (i.e., HBV surface antigen [HBsAg], total core antibody [anti-HBcAb], and surface antibody [HBsAb]) as follows: complete (all 3 tested), partial (any 1 or 2 tests), or none. We determined the frequency of inappropriate HBV testing (HBV e-antigen, anti-HBcAb IgM, or HBV DNA without a positive HBsAg or total anti-HBcAb) and used multivariable regression to assess factors associated with complete HBV screening. RESULTS: Among 678 subjects initiating TCZ, 194 (29%) completed appropriate HBV screening, 307 (45%) had partial screening, and 177 (26%) had none. Among 391 subjects initiating TOF, 94 (24%) completed appropriate HBV screening, 195 (50%) had partial screening, and 102 (26%) had none. Inappropriate testing was performed in 22% of subjects. Race was associated with complete HBV screening (White vs non-White: OR 0.74, 95% CI 0.57-0.95), whereas prior immunosuppression was not (conventional synthetic disease-modifying antirheumatic drugs [DMARDs]: OR 1.05, 95% CI 0.72-1.55; biologic DMARDs: OR 0.73, 95% CI 0.48-1.12). CONCLUSION: Patients initiating TCZ or TOF are infrequently screened for HBV despite recommendations from the AASLD and CDC.
Authors: Cindy M Weinbaum; Ian Williams; Eric E Mast; Susan A Wang; Lyn Finelli; Annemarie Wasley; Stephanie M Neitzel; John W Ward Journal: MMWR Recomm Rep Date: 2008-09-19
Authors: Vivian P Bykerk; Pooneh Akhavan; Glen S Hazlewood; Orit Schieir; Anne Dooley; Boulos Haraoui; Majed Khraishi; Sharon A Leclercq; Jean Légaré; Diane P Mosher; James Pencharz; Janet E Pope; John Thomson; Carter Thorne; Michel Zummer; Claire Bombardier Journal: J Rheumatol Date: 2011-09-15 Impact factor: 4.666
Authors: Rohit Loomba; Ayana Rowley; Robert Wesley; T Jake Liang; Jay H Hoofnagle; Frank Pucino; Gyorgy Csako Journal: Ann Intern Med Date: 2008-04-01 Impact factor: 25.391
Authors: Jessica P Hwang; Michael J Fisch; Hong Zhang; Michael A Kallen; Mark J Routbort; Lincy S Lal; John M Vierling; Maria E Suarez-Almazor Journal: J Oncol Pract Date: 2012-06-12 Impact factor: 3.840
Authors: Alissa Visram; Kelvin K W Chan; Phyllis McGee; Jordana Boro; Lisa K Hicks; Jordan J Feld Journal: PLoS One Date: 2015-04-15 Impact factor: 3.240
Authors: Naomi Serling-Boyd; Amir M Mohareb; Arthur Y Kim; Emily P Hyle; Zachary S Wallace Journal: Ann Rheum Dis Date: 2020-07-30 Impact factor: 19.103
Authors: Robert G Gish; Chari A Cohen; Joan M Block; Carol L Brosgart; Timothy M Block; Ryan Clary; Loc T Le; Michael H Ninburg; Lorren Sandt; Kris V Kowdley Journal: Hepatology Date: 2015-09-29 Impact factor: 17.425